MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.25
-1.17
-3.30%
Closed 16:00 05/05 EDT
OPEN
35.66
PREV CLOSE
35.42
HIGH
36.48
LOW
34.00
VOLUME
66.49K
TURNOVER
--
52 WEEK HIGH
46.32
52 WEEK LOW
15.48
MARKET CAP
385.58M
P/E (TTM)
93.94
1D
5D
1M
3M
1Y
5Y
XOMA EPS misses by $0.55, misses on revenue
XOMA (XOMA): Q1 GAAP EPS of -$0.70 misses by $0.55.Revenue of $0.4M (-50.0% Y/Y) misses by $1.66M.Company ended the first quarter of 2021 with $67.8M in cash.The Company continues to
Seekingalpha · 22m ago
BRIEF-XOMA Posts Q1 Revenue Of $400,000
reuters.com · 39m ago
XOMA Q1 EPS $(0.70) Down From $(0.49) YoY, Sales $375.00K Down From $804.00K YoY
XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.70) per share. This is a 42.86 percent decrease over losses of $(0.49) per share from the same period last year. The company reported $375.00 thousand in sales this
Benzinga · 45m ago
-- Earnings Flash (XOMA) XOMA CORPORATION Posts Q1 Revenue $0.4M
MT Newswires · 4h ago
DJ XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
Dow Jones · 3d ago
XOMA gets milestone payment from Janssen Biotech
XOMA (XOMA) announces that it has earned a $0.5M milestone payment from Janssen Biotech, as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of
Seekingalpha · 3d ago
XOMA Earns $500K Milestone For First Patient Dosed In Phase 3 Development Program
XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed
Benzinga · 3d ago
Global Antibody Library Technology Market Size, Share Report 2021-2027: Detailed Analysis of the Market Structure Along with Production Capacity Estimates, Production Sites, Area Served, and Product Types
Apr 28, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Antibody Library Technology...
The Express Wire · 04/28 13:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XOMA. Analyze the recent business situations of XOMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XOMA stock price target is 48.50 with a high estimate of 56.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 6.93M
% Owned: 61.58%
Shares Outstanding: 11.26M
TypeInstitutionsShares
Increased
18
215.32K
New
11
100.69K
Decreased
11
106.24K
Sold Out
6
90.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Non-Executive Chairman/Independent Director
W. Denman Van Ness
Chief Executive Officer/Director
James Neal
Chief Financial Officer/Senior Vice President
Thomas Burns
Chief Financial Officer/Vice President - Finance
William Garrard
Independent Director
Natasha Hernday
Independent Director
Barbara Kosacz
Independent Director
Joseph Limber
Independent Director
Matthew Perry
Independent Director
Jack Wyszomierski
No Data
  • All
  • Financials
  • Insiders
More
About XOMA
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.